



|  |  |
|--|--|
| <b>PATIENT</b>   | <b>PRESENTING CLINICAL SIGNS</b>   |
| Buttercup Martin   | presenting for acute on chronic episode of GI upset -pt has been vomiting and having diarrhea on and off for approx 1-1.5 years -in the last 3 days, she has been vomiting profusely and having diarrhea, refusing to eat -has lost 8lbs in 3 month Current Medications Cerenia, Metronidazole, Pro-biotic   |
| <b>SPECIES</b>   | Abnormal PE/Chem/CBC/UA Results: Labwork done on 12/7/21 -CBC- mild lymphopenia -Chem- Mild elevation of ALKP (343U/dL) -T4-wnl SNAP cPLI- abnormal  |
| Canine   |  |
| <b>BREED</b>   | <b>ULTRASONOGRAPHIC EXAMINATION OF THE ABDOMEN</b>   |
| Golden Retriever   | <b>Urinary System</b>  |
| <b>SEX</b>   | The urinary bladder presented variably thickened ventroapical to dorsal-apical urinary bladder wall. The luminal margin of the thickened urinary bladder wall was mildly asymmetrical in contour. Mural mineralization or echogenic foci within the thickened areas of the urinary bladder wall was not present. The urinary bladder, trigone, cystourethral junction, and visible pelvic urethra exhibited normal tone to a depth of 2.0 cm. Anechoic urine was present in the lumen with no uroliths, sediment, or calculi. The ureteral papillae were normal. The ureters were not visible which is normal. |
| FS   |  |
| <b>AGE</b>   | The area of the aortic trifurcation was free of pathology.   |
| 13 years   | Normal size and margination were present in the kidneys. A normal 1:3 cortex / medulla ratio was maintained. The medulla and cortices were uniform in texture with some increased echogenicity and mild loss of corticomedullary symmetry and definition expected for the age of the patient. No evidence of pelvic dilation was present. The left kidney measured 6.8 cm in length. The right kidney measured 7.5 cm in length.   |
| <b>WEIGHT</b>  | <b>Adrenal Glands</b>  |
| 30 kgs   | The left adrenal gland was uniform in size and contour with a uniformly hypoechoic parenchyma. The left adrenal gland measured 2.9 cm length x 0.71 cm width at the caudal pole. The right adrenal gland was uniform in size and contour with a uniformly hypoechoic parenchyma. The right adrenal gland measured 3.2 cm length x 0.44 cm width at the caudal pole.  |
| <b>INTERPRETED BY</b>                                    | <b>Spleen</b>  |
| R. McKenzie Daniel,<br>DVM, DABVP<br>(Canine and Feline) | The spleen exhibited primarily finely textured parenchyma which was hyperechoic to the liver and renal cortical parenchyma. Mild generalized parenchyma heterogeneity was present without evidence of nodular changes. The capsule was smooth and regular without apparent expansion. The splenic vasculature at the hilus was normal in volume with no evidence of congestion or thrombosis. The parenchymal heterogeneity is likely consistent with benign changes such as extramedullary hematopoiesis or age-related remodeling with minor potential for inflammatory or neoplastic disease.               |
| <b>IMAGING PERFORMED BY</b>                              | <b>Liver/ Gallbladder</b>  |
| Jenna Walsh, CVT   | The liver was subjectively normal in size, structure, and contour. The liver exhibited generalized mild increased echogenicity with a moderate coarse echotexture and subjective mild to benign  |
| <b>HOSPITAL NAME</b>                                     |  |
| Silver Creek AC  |  |
| <b>REFERRING VET</b>                                     |  |
| Dr. Ceremuga   |  |
| <b>INVOICE</b>   |  |
| 12784  |  |
| <b>DATE</b>  |  |
| 12/9/21  |  |



|  |  |
|--|--|
| <b>PATIENT</b>   | parenchymal remodeling. A focal, hyperechoic, well-demarcated nodule was noted in the left ventral liver. A moderately expansive, nonhomogeneously echogenic to cystic mass was present in the area of the right mid to lateral caudate liver, measuring 11.0 cm x 5.0 cm. The hepatic and portal vasculature were normal in appearance without signs of congestion. The gallbladder was non-distended in size with mild gallbladder debris. The cystic and common bile ducts were normal. |
| Buttercup Martin   |  |
| <b>SPECIES</b>   |  |
| Canine   |  |
| <b>BREED</b>   |  |
| Golden Retriever   |  |
| <b>SEX</b>   |  |
| FS   |  |
| <b>AGE</b>   |  |
| 13 years   |  |
| <b>WEIGHT</b>  |  |
| 30 kgs   |  |
| <b>INTERPRETED BY</b>                                    |  |
| R. McKenzie Daniel,<br>DVM, DABVP<br>(Canine and Feline) |  |
| <b>IMAGING PERFORMED BY</b>                              |  |
| Jenna Walsh, CVT   |  |
| <b>HOSPITAL NAME</b>                                     |  |
| Silver Creek AC  |  |
| <b>REFERRING VET</b>                                     |  |
| Dr. Ceremuga   |  |
| <b>INVOICE</b>   |  |
| 12784  |  |
| <b>DATE</b>  |  |
| 12/9/21  |  |

### ***Gastrointestinal***

The stomach presented intact yet subjective thickened walls. The stomach lumen was empty with mild luminal gas. The gastric body wall width measured 0.50 cm.

The small intestine exhibited generalized intact wall layering yet altered muscularis / mucosa ratio owing to propensity for mildly prominent muscularis layer, as well as mildly echogenic to prominent submucosa layer. The duodenum wall width measured 0.84 cm. The jejunum wall width measured up to 0.55 cm.

The colon was sonographically unremarkable with variably formed (formed to semi-formed, somewhat liquid), feces.

### ***Pancreas***

The pancreas was normal in size and contour with heterogeneous to mildly hypoechoic parenchyma compared to adjacent omentum. No signs of active inflammation or neoplasia.

### ***Free Abdomen***

Small pockets of scant free fluid were noted in the cranial abdomen. No overt lymphadenopathy was noted.

### **ULTRASONOGRAPHIC FINDINGS**

#### ***Primary Findings***

- Variably thickened apical urinary bladder
- Generalized nonhomogeneous to focally nodular liver with right mid to lateral and caudate mass
- Hypoechoic to heterogeneous pancreas
- Gastroenteropathy - likely chronic

### **INTERPRETATION OF THE FINDINGS & FURTHER RECOMMENDATIONS**

The thickened apical urinary bladder may indicate cystitis. Potential for emerging neoplastic criteria cannot be excluded. Screening BRAF Assay may be considered.

FNA of the hepatic mass, as well as hepatic parenchyma for screening cytology, assuming normal clotting status, could be considered. The mass, as well as the nodule, were nonspecific with



**PATIENT**

Buttercup Martin

**SPECIES**

Canine

**BREED**

Golden Retriever

**SEX**

FS

**AGE**

13 years

**WEIGHT**

30 kgs

**INTERPRETED BY**

R. McKenzie Daniel,  
DVM, DABVP  
(Canine and Feline)

**IMAGING PERFORMED BY**

Jenna Walsh, CVT

**HOSPITAL NAME**

Silver Creek AC

**REFERRING VET**

Dr. Ceremuga

**INVOICE**


12784


**DATE**

12/9/21

considerations including granuloma, hyperplasia, with primary concern for neoplasia specifically in the right to caudate liver.

In patients with chronic gastrointestinal signs, chronic to chronic active pancreatitis, dysbiosis, dietary intolerance / food hypersensitivity, IBD or intestinal neoplasia may be possible, all of which may be considerations in this case. A GI panel to include PLI/TLI/Cobalamin/Folate is recommended. In addition to current therapy, hydrolyzed diet trial +/- broad spectrum prophylactic deworming may prove beneficial. Intestinal biopsies would be ideal for a definitive diagnosis. Empirical IBD protocol could be considered if biopsies are not possible.





**PATIENT**

Buttercup Martin

**SPECIES**

Canine

**BREED**

Golden Retriever

**SEX**

FS

**AGE**

13 years

**WEIGHT**

30 kgs

**INTERPRETED BY**

R. McKenzie Daniel,  
DVM, DABVP  
(Canine and Feline)

**IMAGING PERFORMED BY**

Jenna Walsh, CVT

**HOSPITAL NAME**

Silver Creek AC

**REFERRING VET**


Dr. Ceremuga

**INVOICE**

12784

**DATE**


12/9/21



The information and recommendations provided are based on the images presented by the referring veterinarian. No evaluation can be communicated regarding pathology that was not visible in the image/video clips provided.

Thank you for this referral. If the clinical or image interpretation does not parallel your findings or if I can be of any further assistance please contact me.

R. McKenzie Daniel, DVM, DABVP (Canine / Feline Practice)  
info@SonoPath.com



**PATIENT**

Buttercup Martin

**SPECIES**

Canine

**BREED**

Golden Retriever

**SEX**

FS

**AGE**

13 years

**WEIGHT**

30 kgs

**INTERPRETED BY**

R. McKenzie Daniel,  
DVM, DABVP  
(Canine and Feline)

**IMAGING PERFORMED BY**

Jenna Walsh, CVT

**HOSPITAL NAME**

Silver Creek AC

**REFERRING VET**

Dr. Ceremuga

**INVOICE**

12784

**DATE**

12/9/21

**Canine Inflammatory Bowel Disease (IBD)**


<http://www.sonopath.com/K9IBD>

**Description:** Inflammatory bowel disease (IBD) occurs when bowel inflammation results either from an aberrant immune response or an appropriate immune response to a normal luminal resident pathogen. It is thought that the immune response, once initiated, becomes self-perpetuating. Currently, this disease is classified as idiopathic. Antibiotic responsive diarrhea (ARD) and food responsive diarrhea (FRD) are similar yet separately classified enteropathies.

**Clinical Signs:** The most common form of canine IBD is lymphoplasmacytic enteritis (LPE); it is typically seen in middle-aged to older dogs. The most common clinical signs include diarrhea, vomiting, anorexia, and weight loss. Diarrhea can be identified as originating from the small intestine (indicated by weight loss and large volume watery stools), large bowel (indicated by tenesmus, hematochezia, increased frequency of small volumes of diarrhea, and mucoid feces), or both.

**Diagnostics:** In order to differentiate IBD from underlying lymphoma or other conditions, it is important to acquire tissue samples. Tissue samples enable the practitioner to classify the cell type, grade the degree of cellular infiltration, evaluate for the presence of fibrosis, and ultimately gauge how aggressive the therapy must be in order to adequately treat the disease process and prevent irreversible damage. At minimum, endoscopic biopsies of the duodenum and ileum are recommended; jejunal biopsies may also be necessary. Biopsy samples must contain full villus structures (not just the friable tips of villi), ideally down to the level of the muscularis. Presentations of IBD associated with only the ileum are becoming increasingly common. Although the ileum can be a difficult area to access endoscopically, it can be reached via the colon. If indicated, we therefore suggest that an experienced endoscopist be used to obtain ileal biopsies to improve the chances of acquiring accurate results. In general, 6-8 samples obtained from various regions by an experienced practitioner should suffice; however, it is important to remember that the disease may not be diffuse, and that abnormalities may be found only in a portion of the samples. Six to seven adequate samples or 10-15 marginal samples are needed for dogs, whereas fewer samples are typically required to obtain a diagnosis for cats. Crypt lesions within the duodenum are more difficult to diagnose and may require a larger number of samples (13 adequate or 28 marginal). Thus, it is critical that the pathologist has an appropriate number of samples at his or her disposal.

Grading of IBD is based on architectural disruption of the invaded tissues. The World Small Animal Veterinary Association (WSAVA) International Gastrointestinal (GI) Standardization Group developed specific criteria to diagnose and treat canine IBD, which include guidelines on obtaining and interpreting endoscopic samples. Mild forms lack mucosal or glandular disruption, and there is no fibrosis of the lamina propria. Severe IBD presents as architectural disruption with ulceration, necrosis, villous atrophy, glandular loss/hypoplasia, and fibrosis of the lamina propria; however, clinical signs do not always correlate with the severity of the histological changes.



**PATIENT**

Buttercup Martin

**SPECIES**

Canine

**BREED**

Golden Retriever

**SEX**

FS

**AGE**

13 years

**WEIGHT**

30 kgs

**INTERPRETED BY**

R. McKenzie Daniel,  
DVM, DABVP  
(Canine and Feline)

**IMAGING PERFORMED BY**

Jenna Walsh, CVT

**HOSPITAL NAME**

Silver Creek AC

**REFERRING VET**

Dr. Ceremuga

**INVOICE**

12784

**DATE**

12/9/21

Ultrasonographic examination of the bowel wall imparts some correlative information for delineating the differences among various intestinal pathologies. Mucosal appearance is key in developing a working diagnosis. To date, there are four primary presentations that can be correlated with particular ultrasonographic appearances; however, biopsies are necessary to confirm the diagnoses:

1. Food intolerance typically presents as a prominent hypoechoic mucosa. Patients experiencing this particular change uniquely may benefit from the use of an alternative protein or hypoallergenic diet trial as a primary treatment option.


2. IBD can present as a hypoechoic mucosa with echogenic stippling visible throughout the mucosal layer. Biopsies should be performed to confirm as IBD responds best to combination therapies, including immunosuppressants. However, mucosal stippling/speckling is a non-specific finding; it is not directly associated with a finding of IBD and can be seen in dogs that do not present clinical signs of GI disease. Changes in mucosal echogenicity may also reflect a finding of IBD.

3. Patients suffering from protein-losing enteropathy (PLE), including lymphangiectasia, display prominent hyperechoic mucosal striations. Again, biopsy is indicated, and multifaceted therapy should be directed towards immune-suppression and reestablishing a positive protein balance.

4. Although the thickening of the muscularis layer and disruption of the submucosal layers are characteristic of lymphoma or other neoplasia, severe IBD may also present sonographically as such. Concurrent mesenteric lymphadenopathy is also suggestive of lymphoma. Note: Bowel tissue that appears to be normal on ultrasound does not preclude the possibility of lymphoma or IBD.

In addition to assessing ultrasound results, one must evaluate serum cobalamin and folate levels. Low or low-normal levels of cobalamin indicate severe jejunal dysfunction; cobalamin may also be low in cases of exocrine pancreatic insufficiency (EPI). With small intestinal bacterial overgrowth (SIBO), folate levels are typically high due to folate production by microbes; however, folate levels may also be low despite SIBO when severe jejunal and ileal mucosal dysfunction occurs. SIBO is not the same as antibiotic-responsive diarrhea (ARD). Definitive diagnosis depends on small intestinal culture results (via endoscopy or laparoscopy) or an assessment of serum unconjugated bile acids (SIBO case values are typically 10-20X normal). Histiocytic ulcerative colitis is most frequent in Boxer dogs, but has been reported in other breeds as well, and is largely responsive to antibiotics, such as enrofloxacin, metronidazole, and amoxicillin.

EPI is a frequent counterpart and differential for IBD. Voluminous pale-colored feces, voracious appetite, weight loss, and diarrhetic feces are typical but not exclusive to EPI. Moreover, these signs are not always present given the long, compensating nature of the gastrointestinal tract. Testing is therefore essential if other causes of weight loss have been ruled out. Malabsorption



**PATIENT**

Buttercup Martin

**SPECIES**

Canine

**BREED**

Golden Retriever

**SEX**

FS

**AGE**

13 years

**WEIGHT**

30 kgs

and parasitism can contribute to mucosal disease and may be concurrent pathologies. Flatulence, borborygmus, and poor hair coat are evidence of a maldigestive/malabsorptive state. A low serum trypsin-like-immunoreactivity test (TLI) is diagnostic for EPI and hypocholesterolemia is typical.

Defining the presence, via biopsy, of concurrent intestinal lymphangiectasia (IL) (dilated mucosal/submucosal lymph vessels) and PLE also helps determine the prognosis and refine treatment protocols. PLE is suspected in hypoalbuminemic patients when hepatic function is normal (based on a normal bile acid profile) and the urine protein-creatinine (UPC) ratio reveals no significant protein loss (or some secondary loss in cases of associated glomerulonephritis from GI immune complex disease). A fecal  $\alpha$ -1 protease inhibitor test can be used to detect protein loss in feces and requires three fecal samples taken on different days. This test is most useful in cases where the patient has concurrent nephropathy and/or hepatic disease, and one is trying to determine if there is concurrent fecal protein loss and whether GI biopsies are necessary. In cases of lymphangiectasia, cholesterol levels and blood lymphocyte numbers are often decreased. Furthermore, ascites secondary to severe hypoalbuminemia (albumin less than 1.5 g/dl) can result in concurrent loss of anti-thrombin III (AT III) (50,000 Dalton MW similar to albumin). AT III deficiency can lead to a prothrombotic state, which can result in thromboembolic disease; anti-thrombotic medications may be necessary (see below). Clinically, practitioners should monitor for signs of embolic disease and monitor coagulation parameters, such as FDP, D-dimer, PT, APTT, and fibrinogen.

**INTERPRETED BY**

R. McKenzie Daniel,  
DVM, DABVP  
(Canine and Feline)

**IMAGING PERFORMED BY**

Jenna Walsh, CVT

**HOSPITAL NAME**

Silver Creek AC

**REFERRING VET**

Dr. Ceremuga

**INVOICE**


12784

**DATE**


12/9/21

Eosinophilic IBD is less common and can be associated with a food allergy or parasitism. Thus, it may respond well to strict elimination diets and/or anti-parasitides. Certain dog breeds, such as Boxers, Dobermans, German Shepherds, and Rottweilers, appear to be more predisposed to eosinophilic IBD. Severe eosinophilic enteritis can cause significant PLE in some patients. Ruling out concurrent parasitic and protozoal infection is critical in all patients, and appropriate diagnostic tests include standard fecal floatation, assessment for *Giardia* with a zinc sulfate concentration technique, fecal ELISA, or a direct fluorescent antibody test. A fecal PCR test can screen for various infections, such as *Campylobacter coli*, *Campylobacter jejuni*, canine distemper virus (CDV), canine enteric coronavirus (CECoV), canine parvovirus 2 (CPV-2), *Clostridium perfringens* enterotoxin A (CPEA) gene, *Cryptosporidium* spp., *Giardia* spp., and *Salmonella* spp. Colonic scrapings can be done to evaluate for evidence of fungal disease in geographically affected regions. Empirical deworming is reasonable in the management of these patients.

**Treatment:** The first line of therapy for IBD is dietary; a hypoallergenic food trial should be assayed for a minimum of 12 weeks. Diets that include hydrolyzed proteins diets are preferable. If a dog responds favorably, then a novel single-source protein diet can be tried using protein sources such as whitefish, salmon, venison, or kangaroo. In addition, omega-3 fatty acids can be supplemented as natural anti-inflammatory agents; however, most therapeutic diets already contain enhanced levels of omega-3 fatty acids. Supplemental, fermentable fiber sources stimulate beneficial microbial fermentation, thereby releasing volatile fatty acids for colonocyte nutrition and enhancing overall colonic health. Better colonic health has been documented to have many upstream effects, such as bolstered immunity and improved peristalsis and neuroendocrine



|  |  |
|--|--|
| <b>PATIENT</b>   | function. In the face of PLE and lymphangiectasia, a fat-restricted diet is preferred given the loss of cholesterol and fats through the dilated intestinal lacteals. However, supplementation with medium chain triglycerides (MCT) is beneficial as these are mostly absorbed directly into the portal system, bypassing the lymphatics. Their use, in combination with a fat-restricted diet, may enhance caloric intake and management. Probiotic supplementation should also be considered to help normalize the GI flora (i.e., Purina Veterinary Diets® FortiFlora®).   |
| Buttercup Martin   |  |
| <b>SPECIES</b>   | The management of SIBO includes metronidazole (10-20 mg/kg PO BID), tylosin (10-20 mg/kg PO BID), oxytetracycline (20 mg/kg PO BID-TID), or amoxicillin (10-20 mg/kg PO BID). <i>Helicobacter</i> and <i>Campylobacter</i> species are often found upon GI biopsy and may also play a role in the development of clinical signs. Their significance at this point remains unclear; however, <i>Helicobacter</i> is associated with gastric ulcerative disease in humans. Definitive diagnosis depends on gastric biopsy or the less invasive urea breath test, which is highly sensitive and specific for urease-containing bacteria. Coverage for 14-21 days with combinations of amoxicillin, metronidazole, bismuth subsalicylate, and an antacid, such as famotidine or omeprazole, are standard, but eradication rates are variable. Please refer to the chapter on “Canine Erosive Gastritis and Duodenitis” for additional information.   |
| Canine   |  |
| <b>BREED</b>   | The pharmacological treatment of IBD should proceed as follows: for cases of colitis (with no upper GI signs), sulfasalazine (SASA) can be administered at a standard dose of 20-30 mg/kg PO TID, but can be dosed up to 50 mg/kg TID or a maximum dose of 1 gram TID in refractory patients. One suggested protocol entails administering 12.5mg/kg PO TID of SASA for 4 weeks before modifying the dosage. A gradual weaning of the effective dose by 25% every 2 weeks can be attempted once the 12-week food trial has allowed for elimination of allergen accumulation. Although not common, keratoconjunctivitis sicca (KCS) can occur as an untoward side effect of SASA. Owners should be made aware of this possibility, and patients should be monitored for any development of ocular signs. In dogs that cannot tolerate SASA, oral 5-ASA preparations, such as olsalazine (10-20 mg/kg PO TID) or mesalamine, can be utilized; however, we still have little information about the effects of these medications in dogs and KCS remains a possible negative sequelae. After signs have been in remission for 2-3 months, gradual reduction and withdrawal of immunosuppressive therapy may be possible. |
| Golden Retriever   |  |
| <b>SEX</b>   | Ideally, prednisone or prednisolone should only be administered once histopathological results confirm IBD and rule out lymphoma. The administration of prednisone prior to biopsy might mask the lymphoma and make it more difficult to achieve a definitive diagnosis. The use of prednisone in advance of a chemotherapeutic protocol can result in multi-drug resistance, thereby lessening the effectiveness of the chemotherapy. In clinical practice, trial therapies are commonly initiated in patients with typical clinical signs of IBD, in cases where infectious causes have been excluded, and when biopsies are unfeasible due to financial constraints or a condition such as severe hypoalbuminemia. Ultimately, if prednisone is being used empirically, then chemotherapy will not be as effective in this population of patients.  |
| FS   |  |
| <b>AGE</b>   |  |
| 13 years   |  |
| <b>WEIGHT</b>  |  |
| 30 kgs   |  |
| <b>INTERPRETED BY</b>                                    |  |
| R. McKenzie Daniel,<br>DVM, DABVP<br>(Canine and Feline) |  |
| <b>IMAGING PERFORMED BY</b>                              |  |
| Jenna Walsh, CVT   |  |
| <b>HOSPITAL NAME</b>                                     |  |
| Silver Creek AC  |  |
| <b>REFERRING VET</b>                                     |  |
| Dr. Ceremuga   |  |
| <b>INVOICE</b>   |  |
| 12784  |  |
| <b>DATE</b>  |  |
| 12/9/21  |  |



**PATIENT**

Buttercup Martin

**SPECIES**

Canine

**BREED**

Golden Retriever

**SEX**

FS

**AGE**

13 years

**WEIGHT**

30 kgs

Prednisone should be administered at 2 mg/kg/day for a 2-4 week induction period. Subsequently, the patient should be weaned slowly to 1 mg/kg/day, and eventually dosed every other day. In large and giant breed dogs, dosing per body surface area is recommended to avoid overdosing and the precipitation of severe side effects; the recommended dose is 30-40mg/m<sup>2</sup> for large breed dogs. The concurrent administration of metronidazole, azathioprine, and SASA (in cases of concomitant colitis) may allow for a reduced dose of prednisone. Azathioprine can be dosed at 2mg/kg PO Q24hr for approximately 10 days, then 1 mg/kg PO Q24hr, and eventually every other day on alternate days to the prednisone. It should be noted that azathioprine could cause significant bone marrow suppression. Thus, it is recommended that practitioners evaluate a CBC 7 days after the onset of therapy and then on a weekly basis for the first month. Subsequently, CBCs should be performed biweekly for another 1-2 months, and then monthly. Liver enzymes should also be monitored since hepatic necrosis can occur as an idiosyncratic effect. In the long term, azathioprine should be administered on alternating days. Cyclosporine is an alternative immunosuppressant option; however, it can be quite expensive, especially for large breed dogs, and should be dosed at 3-5mg/kg PO Q12-24hr to start. Blood cyclosporine levels should be evaluated 7 days after initiating treatment, and then one can adjust the dosage at that point if need be. Concomitant use of ketoconazole (2.5-5 mg/kg PO BID) inhibits some metabolism of cyclosporine, leading to higher blood concentrations of the latter without increasing the overall dose or cost to the owner. Typically, the dose of cyclosporine can be cut in half when dosed in conjunction with ketoconazole.

**INTERPRETED BY**

R. McKenzie Daniel,  
DVM, DABVP  
(Canine and Feline)

Dogs with histiocytic ulcerative colitis are managed with enrofloxacin 5 mg/kg PO Q24hr, which can also be combined with amoxicillin (20 mg/kg PO BID) and metronidazole (10-15 mg/kg PO BID).

**IMAGING PERFORMED BY**

Jenna Walsh, CVT

Because dogs with severe hypoalbuminemia are predisposed to thromboembolic disease, it is important to administer anti-thrombotic medications, which include low dose aspirin (1 mg/kg PO Q24hr) or clodiprogel (Plavix) at 2 mg/kg PO Q24hr. A one-time loading dose of clodiprogel at 10 mg/kg can be given in the face of a thromboembolic episode. Hypoalbuminemic cases can be temporarily stabilized with colloid therapy, which entails administering hetastarch (5-15 ml/kg IV bolus or 20 ml/kg CRI in maintenance LRS) or, if available, fresh frozen plasma (10-20 mg/kg). The latter is not, however, usually a viable option for regulating serum albumin levels, as very large volumes of plasma are required to effectively correct albumin levels. Human albumin is a concentrated form of albumin, which can be used to improve oncotic pressure when critically necessary. Repeat exposure can result in anaphylaxis but has been used safely in many patients. Raising serum albumin levels is important, especially if surgical biopsies are to be obtained, as severe hypoalbuminemia could cause delays in the healing process and incite dehiscence. Providing oncotic support may also be necessary while instituting a more definitive treatment.

**HOSPITAL NAME**

Silver Creek AC

**REFERRING VET**

Dr. Ceremuga


**INVOICE**

12784

**DATE**

12/9/21

Pancreatic enzyme supplementation is indicated for cases with confirmed concurrent EPI. Low or low-normal B<sub>12</sub> (cobalamin) levels should be treated as well. Recent research suggests that the current veterinary reference range for cobalamin may be inaccurate at the lower limit. That information, coupled with emerging knowledge that many patients suffer from ileal disease, which



|  |   |
|--|---|
| <b>PATIENT</b>   | affects absorption, suggests that we may not be treating these patients adequately. Cobalamin injections (50 µg/kg SC weekly for 6 weeks, then every other week for 6 weeks, then monthly) are recommended; folate and vitamin B can also be given orally. B <sub>12</sub> can be reevaluated after the initial 12-week induction schedule. It is currently recommended to continue monthly treatments in patients displaying any continued IBD signs. Moreover, some research suggests that discontinuing B <sub>12</sub> supplementation may be linked to the recrudescence of signs. |
| Buttercup Martin   |   |
| <b>SPECIES</b>   |   |
| Canine   |   |
| <b>BREED</b>   |   |
| Golden Retriever   |   |
| <b>SEX</b>   |   |
| FS   |   |
| <b>AGE</b>   |   |
| 13 years   |   |
| <b>WEIGHT</b>  |   |
| 30 kgs   |   |
| <b>INTERPRETED BY</b>                                    |   |
| R. McKenzie Daniel,<br>DVM, DABVP<br>(Canine and Feline) |   |
| <b>IMAGING PERFORMED BY</b>                              |   |
| Jenna Walsh, CVT   |   |
| <b>HOSPITAL NAME</b>                                     |   |
| Silver Creek AC  |   |
| <b>REFERRING VET</b>                                     |   |
| Dr. Ceremuga   |   |
| <b>INVOICE</b>   |   |
| 12784  |   |
| <b>DATE</b>  |   |
| 12/9/21  |   |

**Conclusion:** IBD cases can be very challenging to diagnose and treat. Educating the owner on the importance of securing an accurate diagnosis and maintaining a long-term course of treatment in order to see improvements is recommended for better compliance and success with patients.

### References:

Allenspach K. Diseases of the large intestine. In: Ettinger SJ, Feldman EC, eds. *Textbook of Veterinary Internal Medicine 7th ed.* Philadelphia, PA: WB Saunders; 2010:1573-94.

Allenspach K, Rüfenacht S, Sauter S, et al. Pharmacokinetics and clinical efficacy of cyclosporine treatment of dogs with steroid refractory inflammatory bowel disease. *J Vet Intern Med* 2006;20(2):239-44.

Dijkstra M, Kraus JS, Bosje JT, Den Hertog E. *Tijdschr Diergeneeskd* 2010;135(10):406-12.


Flickinger EA, Schreijen EM, Patil AR, et al. Nutrient digestibilities, microbial populations, and protein catabolites as affected by fructan supplementation of dog diets. *J Anim Sci* 2003;81(8):2008-18.

Gaschen L, Kircher P, Stussi A, et al. Comparison of ultrasonographic findings with clinical activity index (CIBDAI) and diagnosis in dogs with chronic enteropathies. *Vet Radiol Ultrasound* 2008;49(1):56-64.

Grieshop CM, Flickinger EA, Fahey GC, Jr. Oral administration of arabinogalactan affects immune status and fecal microbial populations in dogs. *J Nutr* 2002;132(3):478-82.

Hamer HM, Jonkers D, et al. Review article: the role of butyrate on colonic function. *Aliment Pharmacol Ther* 2008;27(2):104-19.

Powell LL. Colloid therapy and concentrated albumin transfusions. Proceedings from the American College of Veterinary Internal Medicine, Seattle, WA, June 4-7, 2013.



**PATIENT**

Buttercup Martin

Viganó F, Perissinotto L, Bosco VRF. Administration of 5% human serum albumin in critically ill small animal patients with hypoalbuminemia: 418 dogs and 170 cats (1994-2008). *J Vet Emerg Crit Care* 2010;20(2):237-43.

**SPECIES**

Canine

Washabau RJ. Endoscopic, biopsy, and histopathologic guidelines in the diagnosis of gastrointestinal inflammation. Proceedings from the American College of Veterinary Internal Medicine, Denver, CO, June 15-18, 2011.

**BREED**

Golden Retriever

Washabau RJ, Day MJ, Willard MD, et al. ACVIM consensus statement on gastrointestinal inflammation. *J Vet Intern Med* 2010;24:10-26.

**SEX**

FS

Zwingenberger AL, Marks SL, Baker TW, Moore PF. Ultrasonographic evaluation of the muscularis propria in cats with diffuse small intestinal lymphoma or inflammatory bowel disease. *J Vet Intern Med* 2010;24(2):289-92.

**AGE**

13 years

**WEIGHT**

30 kgs

**INTERPRETED BY**

R. McKenzie Daniel,  
DVM, DABVP  
(Canine and Feline)

**IMAGING PERFORMED BY**

Jenna Walsh, CVT

**HOSPITAL NAME**

Silver Creek AC

**REFERRING VET**

Dr. Ceremuga

**INVOICE**

12784

**DATE**

12/9/21